Department of Urology, Weill Cornell Medical College, New York, New York; Department of Urology, Medical University of Vienna, Austria.
Department of Urology, Weill Cornell Medical College, New York, New York; Department of Urology, Medical University of Vienna, Austria; Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas.
J Urol. 2017 Dec;198(6):1269-1277. doi: 10.1016/j.juro.2017.06.096. Epub 2017 Jul 12.
To our knowledge the frequency and prognostic significance of PTEN protein expression in upper tract urothelial carcinoma have not yet been investigated in large studies. We analyzed PTEN protein status and its association with disease recurrence and survival outcomes in a large, multi-institutional upper tract urothelial carcinoma cohort.
We retrospectively analyzed the records of 611 patients with upper tract urothelial carcinoma treated with radical nephroureterectomy between 1991 and 2008 at a total of 7 institutions. Median followup was 23 months. Tissue microarrays and immunohistochemical PTEN staining (monoclonal antibody) were performed. Univariable and multivariable Cox regression models were created to address the association of PTEN protein expression with disease recurrence, and cancer specific and overall mortality.
PTEN staining was absent in 45 cases (7.4%). Patients with PTEN loss had significantly advanced pathological tumor stage and grade (p <0.001), and higher rates of lymph node metastasis (p <0.01) and lymphovascular invasion (p <0.001) compared to patients with PTEN expression. PTEN loss was associated with disease recurrence, and cancer specific and overall mortality on univariable Cox regression analyses. However, on multivariable Cox regression analyses adjusted for the effect of standard clinicopathological features PTEN loss was only associated with overall mortality (HR 1.69, 95% CI 1.09-2.61, p = 0.02).
In patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma loss of PTEN protein expression is rare but associated with features of biologically aggressive disease such as higher grade and stage as well as lymph node metastasis. Loss of PTEN expression was associated with overall mortality. PTEN loss seemed to promote worse outcomes in this relatively small group of patients.
据我们所知,PTEN 蛋白在上尿路尿路上皮癌中的表达频率及其预后意义尚未在大型研究中进行过研究。我们分析了 PTEN 蛋白状态及其与疾病复发和生存结果的相关性,该研究纳入了一个大型的多机构上尿路尿路上皮癌队列。
我们回顾性分析了 1991 年至 2008 年间在 7 家机构接受根治性肾输尿管切除术治疗的 611 例上尿路尿路上皮癌患者的记录。中位随访时间为 23 个月。进行了组织微阵列和免疫组织化学 PTEN 染色(单克隆抗体)。创建了单变量和多变量 Cox 回归模型,以研究 PTEN 蛋白表达与疾病复发、癌症特异性和总死亡率的关系。
45 例(7.4%)PTEN 染色缺失。与 PTEN 表达的患者相比,PTEN 缺失的患者具有明显更晚期的病理肿瘤分期和分级(p<0.001),淋巴结转移(p<0.01)和血管淋巴管侵犯(p<0.001)的发生率更高。单变量 Cox 回归分析显示,PTEN 缺失与疾病复发、癌症特异性和总死亡率相关。然而,多变量 Cox 回归分析调整了标准临床病理特征的影响后,PTEN 缺失仅与总死亡率相关(HR 1.69,95%CI 1.09-2.61,p=0.02)。
在上尿路尿路上皮癌患者接受根治性肾输尿管切除术后,PTEN 蛋白表达缺失很少见,但与生物学侵袭性疾病的特征相关,如更高的分级和分期以及淋巴结转移。PTEN 表达缺失与总死亡率相关。PTEN 缺失似乎在上尿路尿路上皮癌患者中,对预后有一定影响。